Iasis Molecular Sciences (IMS) seeks collaborations with leading researchers and top medical centers to accelerate the development and rapid translation of our first-in-class product candidates. We believe these collaborations will maximize our potential to identify state of the art products in areas of wound healing, antimicrobial devices, performance coatings, decorative paints and flooring. Our products are aimed at minimizing pathogen transmission in a variety of different environments, and as additives specific for minimizing fouling in marine environments. Additionally, we believe our proprietary platforms can be deployed in collaboration with strategic partners to create unique products and co-develop state of the art therapies.
Advanced Medical Solutions (AMS), Cheshire, United Kingdom
The AMS Group specializes in the design, development, manufacture and distribution of novel, high performance advanced wound care products, surgical dressings and medical grade materials. IMS has entered a Material Transfer Agreement in late 2018 with The AMS Group to develop Advanced Wound Care Foams at a pilot scale level.
Dr. Hassan Razvi, MD Chief of Urology, St. Joseph’s Health Care and the London Health Sciences Centre, London ON, CA
The collaboration with Dr. Razvi as of October 2016, followed an award from the Congressionally-Directed Medical Research Program of the Department of the Army (D.o.D.). The collaborative investigator-initiated research project is directed toward the development of a next generation urinary catheter utilizing Iasis Molecular Sciences Platform No. 2 antimicrobial composite technology. Dr. Razvi is the author of over 130 scientific papers and 13 book chapters and is currently Professor and Chair of the Division of Urology at The University of Western Ontario and Chief of Urology at St. Joseph’s Health Care London and the London Health Sciences Centre.
Dr. Jeremy Burton PhD. Assistant Professor, Division of Urology, Western University, London Ontario CA; Scientist with Lawson Health Research Institute
The collaboration with Dr. Burton as of October 2016, followed an award from the Congressionally-Directed Medical Research Program of the D.o.D.. The collaborative investigator initiated research project is directed toward the development of a next generation urinary catheter utilizing Iasis Molecular Sciences Platform No. 2 antimicrobial composite technology. Dr. Burton’s laboratory conducts research on the role of microbes in various human conditions with a primary focus upon the microbiome which influences urological conditions. Dr. Burton’s team brings expertise in the area of microbiology, cell culture, and the evaluation of biofilm associated infection.
Hydromer Inc., Branchburg Township, New Jersey (New Collaboration)
IMS has entered into a collaboration with Hydromer Inc. to develop antimicrobial lubricious coatings using IMS Platform No. 1 antiseptics. The first application will be for test articles related to the IMS next generation urinary catheter.
Bentec Medical, Woodland California
Iasis Molecular Sciences has signed a letter of intent with Bentec Medical. They are currently producing a few different prototypes for IMS, including a catheter prototype. These prototypes will be coated and studied for our D.o.D. program.
Dr. George Bonheyo, Senior Research Scientist and the Biotechnology Team Lead in the Energy and Environment Directorate at Pacific Northwest National Laboratory’s Marine Sciences Laboratory in Sequim, Washington
Dr. Bonheyo’s expertise is in the areas of the molecular basis of pathogenesis, biofilms and biofouling, biocorrosion has led to collaborations with IMS directed at marine antifouling and coatings solutions to address microbial contamination in the clinical environment. At present, Dr. Bonheyo has a number of IMS generated test panels under evaluation for a Department of Energy (D.o.E.) funded wave to energy program as well as for below water line vessel coatings.
Global Paints and Performance Coatings Manufacturer
Since 2016, IMS is involved in a collaboration with a global paints and performance coatings manufacturer with interest in the use of our Platform No. 2 antimicrobials as an additive for marine paints to minimize marine fouling. As of 2019, testing is underway in two distinct marine fouling environments (Far East and Europe).
Dr. Dorne Yager PhD – Virginia Commonwealth University (VCU)
Dr. Yager has collaborated with IMS on a variety of projects sponsored by the NIH and the D.O.D.. Dr. Yager has been involved in the wound healing field and has acted as the Director of the VCU Plastic Surgery Research Laboratory since 1990. He has broad experience with design and execution of preclinical models for wound healing. His laboratory utilizes a variety of molecular, biochemical and histological assays to assess wound repair events with a focus on inflammation. Dr. Yager’s collaborations have produced several peer-reviewed publications from his various projects.